Co-Authors
This is a "connection" page, showing publications co-authored by ERICH M STURGIS and HEATH SKINNER.
Connection Strength
0.557
-
Clinical characteristics of patients with multiple potentially human papillomavirus-related malignancies. Head Neck. 2014 Jun; 36(6):819-25.
Score: 0.115
-
Oropharyngeal cancer outcomes correlate with p16 status, multinucleation and immune infiltration. Mod Pathol. 2022 08; 35(8):1045-1054.
Score: 0.052
-
Lymphopenia during radiotherapy in patients with oropharyngeal cancer. Radiother Oncol. 2020 04; 145:95-100.
Score: 0.045
-
Risk of second primary malignancies in head and neck cancer patients treated with definitive radiotherapy. NPJ Precis Oncol. 2019; 3:22.
Score: 0.044
-
Usefulness of surveillance imaging in patients with head and neck cancer who are treated with definitive radiotherapy. Cancer. 2019 06 01; 125(11):1823-1829.
Score: 0.042
-
Radiographic retropharyngeal lymph node involvement in HPV-associated oropharyngeal carcinoma: Patterns of involvement and impact on patient outcomes. Cancer. 2019 05 01; 125(9):1536-1546.
Score: 0.042
-
Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. J Immunother Cancer. 2018 07 11; 6(1):68.
Score: 0.040
-
Significance of Negative Posttreatment 18-FDG PET/CT Imaging in Patients With p16/HPV-Positive Oropharyngeal Cancer. Int J Radiat Oncol Biol Phys. 2018 11 15; 102(4):1029-1035.
Score: 0.040
-
Outcomes of patients diagnosed with carcinoma metastatic to the neck from an unknown primary source and treated with intensity-modulated radiation therapy. Cancer. 2018 04 01; 124(7):1415-1427.
Score: 0.039
-
Clinical Outcomes and Patterns of Disease Recurrence After Intensity Modulated Proton Therapy for Oropharyngeal Squamous Carcinoma. Int J Radiat Oncol Biol Phys. 2016 May 01; 95(1):360-367.
Score: 0.034
-
Comparison of systemic therapies used concurrently with radiation for the treatment of human papillomavirus-associated oropharyngeal cancer. Head Neck. 2016 04; 38 Suppl 1:E1554-61.
Score: 0.034
-
Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients. Cancer Res. 2015 Apr 01; 75(7):1205-15.
Score: 0.032